PharmiWeb.com - Global Pharma News & Resources
26-Apr-2019

Freeline to Present Updates on the Company’s AAV Manufacturing Platform at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting

London, 26 April 2019 Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it will deliver two oral and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting being held from 29th April to 2nd May, 2019 in Washington D.C.

Freeline will present information on their differentiated AAV manufacturing platform and analytical capabilities, leveraged by more than 20 years of AAV experience across the CMC team. The abstracts demonstrate the novelty and built-in quality of the Freeline manufacturing platform. The Freeline approach includes a proprietary plasmid packaging system in combination with adherent culture in the iCELLis® bioreactor platform. This enables Freeline to produce safe, potent and high-quality product at commercial scale. Freeline will also present information on its state-of-the-art analytical methods used for in-depth product characterization to further drive improvements in product quality and safety.    

“We are proud to present updates on our CMC and analytics platform at ASGCT,” commented Markus Hörer, Chief Technology Officer of Freeline. “Our presentations demonstrate how our novel approaches to each step of the AAV production process, from vector design to cassette optimisation to adherent mammalian bioprocessing, have enabled us to reach commercial quality and scale with our platform. Our platform is deployed for all of our programs including our research pipeline and ensures fast progression with high quality products through all development stages.”

The oral presentation details are as follows:

Title: Integration Site Analysis of Ad5 and SV40 Large T Antigen in HEK293T Cells (Abstract 433)
Poster Session Title: Next Generation Gene Vector Engineering and Analytics
Date and Time: 30th April, 4:15 to 4:30 pm
Location: Heights Courtyard 3

Title: A Robust Commercial rAAV-Vector Platform Process Using the iCELLis® 500 Fixed-Bed Bioreactor (Abstract 698)
Poster Session Title: AAV Vectors II
Date and Time: 1st May, 3:45 to 4 pm
Location: Heights Courtyard 2

The poster presentation details are as follows:
Title: Improved Two-Plasmid Packaging System for Manufacturing of AAV Vectors with High Quality and Consistency (Abstract 334)
Poster Session Title: Vector and Cell Engineering, Production or Manufacturing
Date and Time: 29th April, Poster session I, 5 to 6 pm
Location: Columbia Hall 

Title: Analytical Ultracentrifugation as a Qualified, Stability-Indicating Method for Monitoring AAV Capsid Integrity and Degradation (Abstract 479)
Poster Session Title: Next Generation Gene Vector Engineering and Analytics
Date and Time: 30th April, Poster session II, 5 to 6 pm
Location: Columbia Hall

Editor Details

Last Updated: 26-Apr-2019